Recipharm Subsidiary Files Infectious Disease Drug Application in European Markets
News Dec 17, 2013
RPH Pharmaceuticals AB has announced the filing of an application for an infectious disease drug product in a range of European countries.
The product has been developed through a partnership with Swedish pharmaceutical company, Astimex Pharma AB, which is set to market the product in the Nordic market.
As a "first in class generic", the product, owned by RPH Pharmaceuticals, will be licensed to third parties for distribution in markets where Astimex presently is not represented.
In addition to the filed application, Astimex and RPH Pharmaceuticals have expanded their collaboration with another manufacturing and development project in which the drug target is another first in class generic approved for use in most of the North European markets.
The collaboration represents joint investments where Recipharm builds a registration dossier, whilst Astimex takes full responsibility for sales and distribution in the Swedish market and RPH Pharmaceuticals can out-license sales and distribution rights in other markets.
Johan Åkerblom, Business Development Manager, RPH Pharmaceuticals commented: “We are delighted that the collaboration with Astimex is proving to be so successful for both our companies. Indeed, we are greatly excited by the pace at which drug products are being developed and licensing, sales and distribution arrangements are being set in place. Furthermore, the sales potential for the collaboration products looks very promising with the infectious disease target being one clear example of this.”
Concept Life Sciences appoints New Group Programme Manager and US Head of SalesNews
Key leadership appointments support integration of the Group and expansion in the US market.READ MORE
Alzheimer’s Drug Discovery Foundation Announces $1.8M in New FundingNews
The Alzheimer’s Drug Discovery Foundation (ADDF) announces nearly $1.8 million in new funding, which reflects a commitment to advancing drugs in or near human clinical trials. All five funded programs are potential treatments for Alzheimer’s disease and other forms of dementia.READ MORE